jeremy, Author at FACIT

FACIT broadens Executive-in-Residence program to capitalize on Ontario IP

Posted on November 30, 2021 (October 4, 2022)

November 30, 2021 – November 4, 2021 – The appointment broadens the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.

FACIT Features: Radiant Biotherapeutics, next-gen biotech developing multabody therapies for cancer

Posted on October 21, 2021 (October 4, 2022)

October 21, 2021 – October 21, 2021 – Radiant received a seed investment from FACIT’s Compass Rose Oncology Fund.

FACIT Features: Replica Analytics, Ottawa-based start-up in health data artificial intelligence

Posted on October 13, 2021 (October 4, 2022)

October 13, 2021 – October 13, 2021 – Having recently announced several collaborations following the closing of a financing round with Nina Capital, Replica has significant momentum behind it.

FACIT’s Prospects Fund invests in two emerging Ontario diagnostics for colorectal and prostate cancers

Posted on September 16, 2021 (September 13, 2024)

September 16, 2021 – September 16, 2021 – Both innovations were previous finalists in FACIT’s 2021 Falcons’ Fortunes pitch competition.

FACIT Features: Turnstone Biologics completes oversubscribed $80M USD Series D Financing

Posted on July 21, 2021 (October 4, 2022)

July 21, 2021 – July 21, 2021 – The start-up seeded by FACIT in collaboration with several Ontario research institutes continues to deepen its roots in Canada and grow on both sides of the border.

FACIT leads seed round in Nanology Labs

Posted on May 18, 2021 (July 4, 2024)

May 18, 2021 – May 18, 2021 – FACIT deploys Ontario First capital, enables rising local start-up to reach critical value inflection point. FACIT has previously supported Nanology, spun out of the University of Toronto, through both its early-stage Prospects Oncology Fund and seed-stage Compass Rose Oncology Fund.

FACIT Features: Notch Therapeutics Closes $85M USD Series A for Renewable Stem Cell-Derived Cancer Immunotherapies

Posted on February 10, 2021 (October 20, 2025)

February 10, 2021 – February 10, 2021 – The financing is one of the largest Series A financing round in Canadian biotech history, notably at a time of heightened interest by Ontario in commercializing homegrown intellectual property.

FACIT crowns 2021 winner of Falcons’ Fortunes pitch competition; announces follow-on investment in 2020 winner, Bridge7 Oncology

Posted on February 4, 2021 (July 4, 2024)

February 4, 2021 – February 4, 2021 – FACIT’s Prospects Oncology Fund and its annual pitch competition help to advance Ontario oncology innovations.

FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario

Posted on January 26, 2021 (July 4, 2024)

January 26, 2021 – January 26, 2021 – Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures.

FACIT fuels promising made-in-Ontario breast cancer therapeutic and medtech innovations through Prospects Oncology Fund

Posted on December 10, 2020 (July 4, 2024)

December 10, 2020 – December 10, 2020 – The newest recipients of Ontario First seed capital include Dr. Rebecca Laposa of the University of Toronto, as well as London-based start-up Multi-Magnetics Inc.

Author: jeremy

Posts by jeremy